Investigating chest physiotherapy effects on lung function in cystic fibrosis patients
Effects of Autogenic Drainage on Ventilation Inhomogeneity in Patients With Cystic Fibrosis
This study is testing if a special breathing technique called autogenic drainage can improve lung function in people with cystic fibrosis when used with aerosol therapy.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 6 Years and up |
| Sex | All |
| Sponsor | Cliniques universitaires Saint-Luc- Université Catholique de Louvain Academic / other |
| Locations | 1 site (Brussels) |
| Trial ID | NCT03655249 on ClinicalTrials.gov |
What this trial studies
This study examines how a specific chest physiotherapy technique, known as autogenic drainage, impacts ventilation inhomogeneity in individuals diagnosed with cystic fibrosis. Participants will undergo assessments using electrical impedance tomography and multiple breath nitrogen washout before, immediately after, and two hours post-intervention. The study employs a cross-over design where each participant will receive either aerosol therapy alone or in combination with chest physiotherapy over two consecutive days. The primary outcome measured will be the lung clearance index (LCI).
Who should consider this trial
Good fit: Ideal candidates for this study are individuals diagnosed with cystic fibrosis who have an FEV1 greater than 40% and can tolerate 30 minutes of chest physiotherapy.
Not a fit: Patients with Burkholderia cepacia or non-tuberculous mycobacteria infections, or those with significant orthopedic, neuromuscular, or cardiac disorders may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve lung function and overall respiratory health in cystic fibrosis patients.
How similar studies have performed: While there have been studies on chest physiotherapy in cystic fibrosis, the specific combination of techniques and assessments in this study may provide novel insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Cystic fibrosis diagnosis * FEV1 \> 40% * Able to sustain 30min of chest physiotherapy Exclusion Criteria: * Presence of Burkoldheria cepacia or non tuberculous mycobacteria * Orthopedic, neuromuscular or cardiac disorder likely to impact respiratory system * Need for supplemental oxygen * Cardiac pacemaker or internal cardiac defibrillator
Where this trial is running
Brussels
- Cliniques universitaires Saint-Luc — Brussels, Belgium (Recruiting)
Study contacts
- Principal investigator: Gregory Reychler, PT, PhD — Cliniques universitaires Saint-Luc- Université Catholique de Louvain
- Study coordinator: William Poncin, PT, PhD
- Email: william.poncin@uclouvain.be
- Phone: +3227642316
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.